Call for patient input on biosimilar infliximab (Merck) for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis
Do you have rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis? We need your valuable input
Health Canada defines biosimilars as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Remicade®).
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar infliximab for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. The originator biologic, or reference product, is infliximab (Remicade®).
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.
These are the questions they are asking: Continue reading
From this year’s EULAR annual conference comes major news for people living with spondyloarthritis (SpA). Based on recommendations from a task force of European and North American patients, rheumatologists, dermatologists, and health professionals, new treat-to-target (T2T) guidelines for SpA were announced that emphasize the importance to set a target in shared decision making between a specialist and patient and carefully monitor the disease in order to improve a patient’s health outcome.
“The T2T recommendations are following the principle that you have to define a target you want to reach and adapt management to reach this target. This is independent of the treatment you use to reach the target,” said Professor Desiree van der Hejde, a professor at Leiden University Medical Centre in the Netherlands. Continue reading
BC PharmaCare is looking for your input on biosimilar etanercept (Erelzi) for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis and rheumatoid arthritis
Biosimilar etanercept (Erelzi) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide your input on biosimilar etanercept for the treatment of ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA). You can give input if you are a B.C. resident and have AS, JIA or RA, a caregiver to someone with AS, JIA or RA, or if your group represents people who live with AS, JIA or RA.
May is ankylosing spondylitis month and to celebrate, we would like to share this question and answer session Arthritis Consumer Experts did with Michael Mallinson, President of the Canadian Spondylitis Association.
Q: Hi, Michael. Can you tell us about your organization?
A: The Canadian Spondylitis Association is a nonprofit national patient association formed in April 2006 to support and to advocate for those suffering from ankylosing spondylitis and associated spondyloarthritis diseases including psoriatic arthritis, enteropathic arthritis and reactive arthritis. Our goal is to be the leader in Canada providing support, education and advocacy for the spondyloarthritis patient community
Q: What are some misconceptions about ankylosing spondylitis?
A: Most people are unaware that AS strikes young people. The typical age of onset is between 17 and 35. Although people are aware that arthritis is a women’s disease, they are surprised when they found out AS has a significantly higher prevalence among men.
Do you have rheumatoid arthritis, ankylosing spondylitis or polyarticular juvenile idiopathic arthritis or care for someone who does? We need your valuable input.
Health Canada defines biosimilars (sometimes referred to as subsequent entry biologics or SEBs) as biologic medicines that are similar to, and would enter the market after, an approved originator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. Biosimilars are not identical to their originator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, biosimilars may have unique efficacy, immunogenicity, and safety profiles that are different from their originator.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for biosimilar etanercept for the treatment of rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis. The originator biologic, or reference product, is etanercept (Enbrel®).
Good news for Arthritis Consumer Experts (ACE) members and subscribers who live with a form of ankylosing spondylitis. Within the arthritis research world, the field of ankylosing spondylitis is rapidly progressing, and very exciting new discoveries are being made. At the American College of Rheumatology (ACR) annual meeting, Dr. Dirk Elewaut, Professor of Rheumatology and Immunology and Chair of the Department of Rheumatology at Ghent University Hospital, Belgium, discussed the importance of gut inflammation in spondyloarthritis.